latest news releases from the newsroom
MediciNova Reports Phase Ib Clinical Study Results for MN-221, a Novel Treatment for Preterm Labor
SAN DIEGO, Aug. 17, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced results from its Phase Ib clinical trial of MN-221 for the treatment of preterm labor. Target plasma concentrations were achieved with an intravenous priming followed by maintenance infusion dosing paradigm. No significant safety concerns with MN-221 were identified in this clinical trial.
NASDAQ Urges OMX Shareholders to Support Superior NASDAQ Offer
NEW YORK, Aug. 17, 2007 (PRIME NEWSWIRE) -- The Nasdaq Stock Market, Inc. (Nasdaq:NDAQ) notes the offer by Bourse Dubai to acquire all of the outstanding stock of OMX AB. NASDAQ remains fully committed to its recommended offer for OMX, which the OMX Board of Directors unanimously recommended OMX shareholders to accept in a joint press release issued on May 25, 2007. Compared to the inferior Bourse Dubai offer, NASDAQ's offer provides superior long-term value, will strengthen the Nordic region as a financial center by providing enhanced opportunities for economic growth throughout the region, and delivers significant benefits for customers and stakeholders of OMX. NASDAQ urges OMX shareholders and stakeholders to support the NASDAQ offer.